TEVA - Teva Pharmaceutical Industries Limited

NYSE - Nasdaq Real Time Price. Currency in USD
20.96
+0.26 (+1.26%)
As of 11:56AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close20.71
Open20.17
Bid20.86 x 500
Ask20.86 x 400
Day's Range20.16 - 21.39
52 Week Range10.85 - 37.94
Volume15,024,209
Avg. Volume27,239,429
Market Cap21.295B
Beta0.68
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.00 (0.00%)
Ex-Dividend Date2017-11-27
1y Target EstN/A
Trade prices are not sourced from all markets
  • Behind Novartis’s 4Q17 Estimates: Innovative Medicines
    Market Realist27 minutes ago

    Behind Novartis’s 4Q17 Estimates: Innovative Medicines

    Novartis’s (NVS) Innovative Medicines segment includes cardio-metabolic products, oncology products, immunology and dermatology products, respiratory products, neuroscience products, and established products. The segment’s contribution is ~67% of NVS’s total revenues.

  • Foreign Stock Roundup: Taiwan Semiconductor Beats, Shell Buys Stake in Silicon Ranch
    Zacks3 hours ago

    Foreign Stock Roundup: Taiwan Semiconductor Beats, Shell Buys Stake in Silicon Ranch

    Global markets largely echoed Wall Street's fortunes over last week.

  • SmarterAnalyst3 hours ago

    Why Teva Pharmaceutical Industries Ltd’s (ADR) Stock Is In The Red Today

    Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) slipped 2% this morning after the generic giant announced that a Phase III registration study evaluating subcutaneously administered reslizumab (110 mg) in a pre-filled syringe did not meet its primary endpoint of significantly reducing the frequency of clinical asthma exacerbations (CAEs) in patients with uncontrolled asthma and elevated blood eosinophils 300/mcL. Additionally, a Phase III claim-support study evaluating subcutaneously administered reslizumab in patients with oral corticosteroid (OCS)-dependent asthma did not meet its primary endpoint of reduction in daily OCS dose.

  • Inside Novartis’s 4Q17 Earnings: Analyst Estimates
    Market Realist4 hours ago

    Inside Novartis’s 4Q17 Earnings: Analyst Estimates

    Novartis’s 4Q17 Earnings: Behind the ExpectationsA look at Novartis’s earnings

  • Reuters4 hours ago

    Teva's asthma treatment fails late-stage studies

    Teva Pharmaceutical Industries said on Monday two late-stage studies testing its treatment for asthma did not meet their main goals. The studies were testing Teva's subcutaneous dosing of reslizumab in ...

  • MarketWatch4 hours ago

    Teva shares decline on negative late-stage trial results for asthma therapy

    Teva Pharmaceutical Industries Ltd. shares slid 3% premarket Monday, after the company said a late-stage trial of an asthma treatment failed to meet its main goal. The company said the therapy, subcutaneously ...

  • Generic-Drug Makers Fall as Justice Department Threatens to Sue
    Bloomberg3 days ago

    Generic-Drug Makers Fall as Justice Department Threatens to Sue

    Shares of generic-drug makers including Mylan NV and Teva Pharmaceutical Industries Ltd. fell after the Justice Department’s antitrust division said it might sue them for damages in a price-fixing probe....

  • Generic-Drug Firms Fall as U.S. Threatens to Sue for Damages
    Bloomberg3 days ago

    Generic-Drug Firms Fall as U.S. Threatens to Sue for Damages

    Shares of generic-drug makers including Mylan NV and Teva Pharmaceutical Industries Ltd. fell after the Justice Department’s antitrust division said it might sue them for damages in a price-fixing probe....

  • How Hospitals Plan To Put Pressure On Generic-Drug Makers
    Investor's Business Daily4 days ago

    How Hospitals Plan To Put Pressure On Generic-Drug Makers

    Generic-drug makers were hit Thursday after hospitals said they would make medicines themselves to circumvent high prices.

  • American City Business Journals4 days ago

    Teva cutting 200+ local jobs as part of broader restructuring plan

    Teva Pharmaceutical Industries will be laying off more than 200 local employees as part of a major restructuring plan designed to save the company $3 billion by the end of 2019. The Israeli generic drug maker, which calls North Wales, Pa. its U.S. headquarters, said last month it would eliminate 14,000 positions globally — more that 25 percent of its total work force — over the next two years. It has about 56,000 employees worldwide including about 2,000 people in North Wales, West Chester and Frazer, Pa.

  • Scoop Up Teva Pharmaceutical Industries Ltd (ADR) on Every Dip
    InvestorPlace4 days ago

    Scoop Up Teva Pharmaceutical Industries Ltd (ADR) on Every Dip

    Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) had a very bad 2017. The government of Israel actually got involved and there were protests in the street because this was a gem of the Israeli business community. TEVA was the largest generic drug manufacturer in the U.S. And it also had a brand drug, Copaxone, that was doing well and represented about 80% of its free cash flow.

  • Teva Pharmaceutical: Still Focused on New Product Launches
    Market Realist5 days ago

    Teva Pharmaceutical: Still Focused on New Product Launches

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? The Vanguard Total International Stock ETF (VXUS) holds 0.09% of its total portfolio in TEVA stock. Teva Pharmaceutical Industries (TEVA) has its biggest value chain in the market as the company’s core strength, which has helped it establish itself as the leading generics pharmaceutical company in the world.

  • How This Biotech Stock Could Top Bigger Rivals In Preventing Migraines
    Investor's Business Daily6 days ago

    How This Biotech Stock Could Top Bigger Rivals In Preventing Migraines

    Alder could successfully compete with larger rivals Amgen, Lilly and Teva in preventing chronic migraines, analysts said Tuesday.

  • InvestorPlace6 days ago

    Strong UnitedHealth Group Inc Earnings Keep Rally Going

    It’s exceedingly difficult to find something to dislike about UnitedHealth Group Inc (NYSE:UNH) stock. In a healthcare sector filled with minefields over the past few years, UnitedHealth stock has tripled over the past four years. Valuation might seem a slight concern, but UNH stock isn’t that expensive on an earnings basis, nor is its balance sheet particularly levered.

  • What’s Teva Pharmaceutical’s Research and Development Strategy?
    Market Realist6 days ago

    What’s Teva Pharmaceutical’s Research and Development Strategy?

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? In December 2017, Teva Pharmaceutical Industries (TEVA) laid out a detailed restructuring plan for the company to turn around its ailing business due to a number of challenges it’s facing.

  • Teva's Trisenox Gets FDA Approval as First-Line Treatment
    Zacks6 days ago

    Teva's Trisenox Gets FDA Approval as First-Line Treatment

    Teva Pharmaceutical (TEVA) receives approval from the FDA for label expansion of its leukemia drug, Trisenox, in first-line setting.

  • How Teva Pharmaceutical Plans to Improve Financial Profile
    Market Realist6 days ago

    How Teva Pharmaceutical Plans to Improve Financial Profile

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? As we saw in the previous part of this series, Teva Pharmaceutical Industries (TEVA) is determined to pay down a considerable amount of its debt totaling $32 billion over the next few years. The company aims to achieve financial stability through improvement in operating profits and stable cash flow generation over the next few years.

  • How Teva Pharmaceutical Plans to Optimize Global Generics
    Market Realist6 days ago

    How Teva Pharmaceutical Plans to Optimize Global Generics

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate?

  • How Teva Pharmaceutical Is Realigning Organizational Structure
    Market Realist7 days ago

    How Teva Pharmaceutical Is Realigning Organizational Structure

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? On December 14, 2017, Teva Pharmaceutical Industries (TEVA) announced its restructuring plan to cut costs by ~$3 billion over the next two years. It expects to witness a major turnaround of its business with the implementation of this plan.

  • What Are Insys Therapeutics’ Top Priorities?
    Market Realist7 days ago

    What Are Insys Therapeutics’ Top Priorities?

    Insys (INSY) is taking strategic steps to restore stakeholder confidence. The company aims to achieve one NDA (or new drug application) per year over the next five years. Insys is targeting treatments for orphan diseases, neurological diseases like pediatric epilepsy, genetic conditions like Prader-Willi syndrome, and treatments for secondary allergic reactions, anorexia, and products for opioid overdose.

  • Teva Pharmaceutical Focusing on Per Product Operating Profits
    Market Realist7 days ago

    Teva Pharmaceutical Focusing on Per Product Operating Profits

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has been focused on maximizing its revenues through its market-leading generics portfolio. The company, however, has been facing stiff competition in the generics market from Mylan (MYL), Gilead Sciences (GILD), and Pfizer (PFE), which has resulted in price erosion in the generics market.

  • Can Teva’s Debt Repayment Plan Deleverage Its Balance Sheet?
    Market Realist7 days ago

    Can Teva’s Debt Repayment Plan Deleverage Its Balance Sheet?

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has a debt of $34 billion on its balance sheet. The company is focused on reducing its net debt obligations to optimum levels over the coming years.

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool9 days ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    These three small biotech stocks saw huge jumps. Can their momentum continue?

  • What’s behind Insys Therapeutics’ Legal Tangles?
    Market Realist10 days ago

    What’s behind Insys Therapeutics’ Legal Tangles?

    Thus, interaction with government agencies occurs regularly. Insys (INSY) has been a part of several government investigations recently. Insys received a subpoena in December 2013 from the inspector general of HHS for an investigation of potential violations that involved HHS programs.

  • Teva's Debt Cut to Junk by Moody's, Adding to Drugmaker's Woes
    Bloomberg10 days ago

    Teva's Debt Cut to Junk by Moody's, Adding to Drugmaker's Woes

    Teva Pharmaceutical Industries Ltd.’s credit rating was cut into junk territory by Moody’s Investors Service, adding to the company’s woes as revenue from its bestselling drug drops and it sells assets ...